TRACON Pharmaceuticals, Inc. (TCON)
OTCMKTS: TCON · Delayed Price · USD
0.655
+0.025 (3.96%)
Jul 25, 2024, 4:00 PM EDT - Market closed
TRACON Pharmaceuticals Revenue
TRACON Pharmaceuticals had revenue of $100.00K in the quarter ending March 31, 2024. This brings the company's revenue in the last twelve months to $12.15M. In the year 2023, TRACON Pharmaceuticals had annual revenue of $12.05M.
Revenue (ttm)
$12.15M
Revenue Growth
n/a
P/S Ratio
0.14
Revenue / Employee
$714,412
Employees
17
Market Cap
1.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 78.71B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
AstraZeneca | 49.13B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
TCON News
- 6 weeks ago - TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients - GlobeNewsWire
- 2 months ago - TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 - GlobeNewsWire
- 3 months ago - TRACON Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 - GlobeNewsWire
- 7 months ago - TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial - GlobeNewsWire
- 8 months ago - TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment - GlobeNewsWire